A study of selective androgen receptor degrader (SARD) compaunds for the treatment of prostate cancer
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs Selective androgen receptor antagonists (Primary) ; Small molecules (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- 15 May 2017 According to a GTx media release, the company plans to initiate this trial in first half of 2018.
- 15 Mar 2017 According to a GTx media release, the company plans to initiate this trial in second half of 2017.
- 31 Aug 2016 New trial record